These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 10818804)

  • 1. [New evidence for the usefulness of an old drug in the treatment of heart failure].
    Oseguera Moguel J
    Rev Invest Clin; 2000; 52(1):14-6. PubMed ID: 10818804
    [No Abstract]   [Full Text] [Related]  

  • 2. [The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):987-8. PubMed ID: 10488324
    [No Abstract]   [Full Text] [Related]  

  • 3. [Value of diuretics and aldosterone antagonists in the treatment of heart failure].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S40-7. PubMed ID: 10535046
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of spironolactone on C-reactive protein levels in patients with heart disease.
    Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD
    Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An old drug provides surprising benefits for heart-failure patients.
    Harv Heart Lett; 1999 Dec; 10(4):5-7. PubMed ID: 10564892
    [No Abstract]   [Full Text] [Related]  

  • 8. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of spironolactone in heart failure should be emphasised.
    Mapstone J; Houston B; Gogarty M
    BMJ; 2000 Sep; 321(7262):706-7. PubMed ID: 11202944
    [No Abstract]   [Full Text] [Related]  

  • 10. What's old is new again. Spironolactone and heart failure.
    Lock M; Chun R
    Can Fam Physician; 1999 Nov; 45():2621-2. PubMed ID: 10587769
    [No Abstract]   [Full Text] [Related]  

  • 11. Spironolactone for heart failure: a worthy addition to therapy.
    Rittenhouse SK
    Adv Nurse Pract; 2001 Jan; 9(1):34-6, 39. PubMed ID: 12416036
    [No Abstract]   [Full Text] [Related]  

  • 12. New hope for heart failure.
    DeMaria A
    Health News; 1999 Sep; 5(11):1-2. PubMed ID: 10513252
    [No Abstract]   [Full Text] [Related]  

  • 13. Spironolactone in left-sided heart failure: how does it fit in?
    Margo KL; Luttermoser G; Shaughnessy AF
    Am Fam Physician; 2001 Oct; 64(8):1393-8. PubMed ID: 11681781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic heart insufficiency should be treated also with spironolactone].
    Kjeldsen KP; Nørgaard A; Thygesen K
    Ugeskr Laeger; 1999 Sep; 161(37):5132. PubMed ID: 10523942
    [No Abstract]   [Full Text] [Related]  

  • 16. [The process of drug development. The "case" of spironolactone].
    De Feo S; Opasich C; Volpi A; Tavazzi L
    Ital Heart J Suppl; 2002 Feb; 3(2):178-86. PubMed ID: 11926024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Randomized Aldactone Evaluation Study (RALES)].
    Uchida K; Nakano S; Kigoshi T
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():330-5. PubMed ID: 15813090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.